DUARTE, Calif.--(BUSINESS WIRE)--Linda Malkas, Ph.D., deputy director of basic research for City of Hope who holds the M.T. & B.A. Ahmadinia Professorship in Molecular Oncology, has been appointed to the governing board of the California Institute for Regenerative Medicine (CIRM), the state’s Stem Cell Agency.
California Treasurer John Chiang made the appointment, saying: “She has had a stellar career in both research and administration, promoting and advancing research in women’s health with a particular focus on breast cancer. Dr. Malkas’ research expertise is in the areas of human cell DNA replication/repair, in biomarker and therapeutic target discovery and development.
“Dr. Malkas is extraordinarily well-qualified for the post. Her résumé certainly reflects that. She was the founding director of the Indiana Center for Breast Cancer Research. She discovered a molecule that can inhibit certain activities in cancerous cells and hopes to move that into clinical trials in the near future,” Chiang added. “She served for five years on a National Cancer Institute (NCI) subcommittee reviewing cancer center designations. She has served as chair on several NCI study panels and recently took on an advisory role on drug approval policy with the Food and Drug Administration.”
Malkas said she is honored by the opportunity to serve California through CIRM’s board.
“The research and technologies developed through this agency have benefited the health of not only Californians but the nation and world itself,” she added. “I am excited to see what the future holds for the work of this agency.”
In addition to her leadership role at City of Hope, Malkas is a professor of molecular and cellular biology at Beckman Research Institute of City of Hope and joint head of the Molecular Oncology Program.
Malkas earned her master’s and doctorate degrees from City University of New York. She has published more than 75 peer-reviewed articles in medical journals and, in her spare time, is a member of the editorial boards for the journals Cancer Research, Cancer Prevention Research, Current Cancer Therapy Reviews and the American Journal of Translational Research.
“We are extremely happy to welcome Dr. Malkas to the Board,” said Jonathan Thomas, Ph.D., J.D., chair of the CIRM board. “Not only has she demonstrated expertise and leadership in science and academia, but the collaborative approach she has shown throughout her career make her an excellent addition to CIRM.”
In her spare time, Malkas enjoys spending time at her ranch with her family and friends. She also enjoys riding her four horses, and taking care of her dogs and cats. She is a lover of the sci-fi genre and enjoys “Star Trek” and vintage sci-fi movies, as well as “Harry Potter” books and films.
About City of Hope
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 47 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of “America’s Best Hospitals” in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.